MedTrace Logo

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

NCT00147745 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2014-04-02

Study results available
· View outcomes & findings →

Summary

This study is designed to assess the potential mechanism of action by which WelChol® (colesevelam) may improve blood glucose control in patients with type 2 diabetes

Conditions

Interventions

DRUG

Colesevelam

Colesevelam 3.8g for 12 weeks

DRUG

Colesevelam matching placebo

Colesevelam matching placebo for 12 weeks

DRUG

Insulin glargine (Lantus)

Insulin glargine for 12 weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00147745 on ClinicalTrials.gov